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Abstract
Introduction
The etiology of hidradenitis suppurativa is not completely 
understood but it is likely multifactorial with some of the 
possible contributing factors including: genetics, hormones, 
and aberrant immune response that causes upregulated 
cytokines (DynaMed Plus, 2016). Risk factors include family 
history, smoking, obesity, mechanical friction, and certain 
medications (DynaMed Plus, 2016).  Traditional treatments 
for this disorder consisted of antibiotics, hormone therapy, 
retinoids, corticosteroid injections, surgical intervention, pain 
management, and patient counselling on weight loss and 
smoking cessation. More recently, the tumor necrosis factor-
alpha (TNF-alpha) inhibitor adalimumab was approved by 
the Food and Drug Administration (FDA) for treating 
hidradenitis suppurativa
Research Question
Literature Review Applicability to Clinical Practice
Acknowledgements
Discussion
• The studies used support the use of adalimumab for 
hidradenitis suppurativa 
• There were no placebo controlled trials found within the 
last ten years to support the use of any of the traditional 
treatment options for hidradenitis suppurativa
• Serious adverse effects rates were higher in patient groups 
that were assigned adalimumab vs the placebo 
• There is no data comparing adalimumab serious adverse 
effects vs the serious adverse effects of any of the 
traditional treatments used
• Adalimumab has only been assessed for moderate-to-
severe hidradenitis suppurativa, therefore the efficacy for 
adalimumab for mild hidradenitis suppurativa is unknown
Hidradenitis suppurativa is a chronic, recurrent follicular 
occlusion disease with painful, sometimes debilitating, 
cutaneous draining lesions and subcutaneous abscesses 
(DynaMed Plus, 2016). Hidradenitis suppurativa is 
understood to be a multifactorial disease that is hard to treat 
in some patients, especially those with a severe form of the 
disease. For this project, the efficacy of adalimumab for 
hidradenitis suppurativa was assessed and whether it is 
more beneficial than traditional treatments used. 
Adalimumab is a TNF-alpha inhibitor which belongs to the 
biologic DMARDs drug class. Kimball et al. (2012) found 
that at week 16 of their trial 3.9% of the placebo patients, 
9.6% of every other week (EOW) dosing of adalimumab 
patients, and 17.6% of every week dosing of adalimumab 
patients achieved clinical response. Patient response 
reports on pain and outcomes were significantly greater in 
the weekly dosed patients vs. placebo group. A study by 
Miller et al. (2011) showed a significant reduction in 
Sartorious score after 6 weeks and an almost significant 
reduction seen after 12 weeks when compared to the 
placebo group (-10.7 vs. 7.5, P=0.024 and -11.3 vs. 5.8, 
P=0.07). Kimball et al. (2016) showed clinical response 
rates at week 12 were significantly higher for the groups 
receiving adalimumab weekly than for the placebo groups: 
41.8% versus 26.0% in PIONEER I (P=0.003) and 58.9% 
versus 27.6% in PIONEER II (P<0.001). DynaMed Plus, 
PubMed, and Cochran Library were searched with key 
words: hidradenitis suppurativa, adalimumab, and treatment.
• In patients with hidradenitis suppurativa is adalimumab 
more effective than traditional treatments to include 
antibiotics, hormone therapy, retinoids, corticosteroid 
injections, surgical intervention, and pain management in 
treatment outcomes?
• In patients with hidradenitis suppurativa does adalimumab 
show better treatment outcomes in patients with severe 
disease vs mild or moderate disease?
• In patients with hidradenitis suppurativa are the side effect 
outcomes associated with adalimumab treatment more 
significant or detrimental than side effect outcomes 
associated with the traditional treatment options?
• Kimbal et al. (2012) found that at week 16, 3.9% of the 
placebo patients (2 of 51), 9.6% of the EOW patients (5 of 
52) and 17.6% of weekly patients (9 of 51) achieved 
clinical response
• Kimbal et al. (2012) also found that serious adverse 
effects rates were 3.9% for placebo, 5.8% for EOW, and 
7.8% for the weekly patients
• “In period I of each study there were significantly more 
patients in the adalimumab group than the placebo group 
that met the primary efficacy end point of clinical response 
at week 12 (PIONEER I: 41.8% vs. 26.0%, P=0.003; 
PIONEER II: 58.9% vs. 27.6%, P<0.001)” (Kimball, 2016)
• Miller et al. (2011) found a significant reduction of the 
Sartorius score after 6 weeks and an almost significant 
reduction after 12 weeks of active treatment when 
compared to the placebo group (-10.7 vs. 7.5, P=0.024 
and -11.3 vs. 5.8, P=0.07)
• Miller et al. (2011) state in their study that although 
adalimumab was well tolerated, there were more adverse 
effects seen in the adalimumab group than the placebo 
group with regard to mild infections. “However, the 
difference was only almost significant (P=0.16 and 
P=0.79, respectively)” (Miller, 2011, p.395). All other 
adverse effects were not significant in the adalimumab 
group when compared to the placebo group
The current guidelines found on DynaMed Plus do 
recommend adalimumab for moderate-to-severe 
hidradenitis suppurativa, which is supported by my 
research. These guidelines from DynaMed are very 
applicable to clinic use, but there is no cure and treatment 
is patient dependent with much trial and error. Hidradenitis 
suppurativa is difficult to treat and should not be treated in 
a primary care setting, this should be maintained by the 
dermatology department. There are several different 
scoring systems used to assess hidradenitis suppurativa 
and dermatologists are better suited to track these scores 
to assess how treatment is going. Some lifestyle 
modifications such as smoking cessation, good control of 
blood sugars with diabetic patients, and weight loss can 
be encouraged in a primary care setting.
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scholarly project.
Statement of the Problem
There is no cure for hidradenitis suppurativa and although 
there are many treatment options available, the traditional 
treatments do not provide adequate relief of symptoms for 
some patients. Adalimumab, though not a cure, may provide 
more beneficial treatment then these traditional options 
alone. This review was needed to evaluate research 
supporting the efficacy of adalimumab for hidradenitis 
suppurativa and to compare the risks and benefits of using 
this medication.
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